| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 13 | 2021 | 301 | 1.730 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 198 | 0.950 |
Why?
|
| Genome-Wide Association Study | 12 | 2023 | 271 | 0.930 |
Why?
|
| Neuroglia | 1 | 2020 | 117 | 0.720 |
Why?
|
| Parkinson Disease | 1 | 2020 | 167 | 0.670 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 125 | 0.660 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 292 | 0.590 |
Why?
|
| Adiposity | 4 | 2023 | 145 | 0.580 |
Why?
|
| Choline | 2 | 2019 | 57 | 0.570 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 86 | 0.560 |
Why?
|
| Colorectal Neoplasms | 7 | 2020 | 413 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2021 | 638 | 0.490 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 336 | 0.470 |
Why?
|
| Neoplasms | 3 | 2020 | 1033 | 0.450 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 528 | 0.440 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 25 | 0.420 |
Why?
|
| Aged | 22 | 2021 | 6448 | 0.420 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 55 | 0.410 |
Why?
|
| Smoking | 5 | 2018 | 903 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 781 | 0.410 |
Why?
|
| Genetic Markers | 1 | 2012 | 118 | 0.410 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 79 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 178 | 0.410 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 206 | 0.390 |
Why?
|
| Glutathione Transferase | 4 | 2017 | 83 | 0.390 |
Why?
|
| Humans | 50 | 2023 | 34853 | 0.380 |
Why?
|
| Leukemia | 4 | 1994 | 54 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2019 | 147 | 0.360 |
Why?
|
| Liver Neoplasms | 3 | 2019 | 195 | 0.350 |
Why?
|
| Japan | 5 | 2021 | 296 | 0.340 |
Why?
|
| Female | 35 | 2023 | 19873 | 0.320 |
Why?
|
| Membrane Glycoproteins | 4 | 1994 | 197 | 0.320 |
Why?
|
| Middle Aged | 22 | 2021 | 9642 | 0.310 |
Why?
|
| Genotype | 7 | 2020 | 641 | 0.290 |
Why?
|
| Male | 28 | 2023 | 18870 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 184 | 0.280 |
Why?
|
| Butadienes | 2 | 2017 | 30 | 0.280 |
Why?
|
| MicroRNAs | 4 | 2020 | 386 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 5 | 2016 | 484 | 0.270 |
Why?
|
| Intra-Abdominal Fat | 2 | 2023 | 39 | 0.260 |
Why?
|
| Prognosis | 9 | 2021 | 707 | 0.260 |
Why?
|
| Nitrosamines | 2 | 2018 | 9 | 0.250 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 2333 | 0.250 |
Why?
|
| Leukocytes | 3 | 1995 | 68 | 0.250 |
Why?
|
| Case-Control Studies | 10 | 2020 | 1056 | 0.240 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 794 | 0.230 |
Why?
|
| CpG Islands | 5 | 2018 | 91 | 0.230 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 269 | 0.220 |
Why?
|
| Up-Regulation | 4 | 2021 | 490 | 0.220 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 600 | 0.210 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2001 | 13 | 0.210 |
Why?
|
| Pancreas | 1 | 2021 | 32 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2001 | 19 | 0.200 |
Why?
|
| Obesity | 3 | 2023 | 965 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 1995 | 392 | 0.200 |
Why?
|
| Gene Regulatory Networks | 3 | 2016 | 115 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2013 | 19 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 181 | 0.200 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2012 | 10 | 0.200 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 59 | 0.190 |
Why?
|
| Diagnostic Test Approval | 1 | 2020 | 1 | 0.190 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2020 | 14 | 0.190 |
Why?
|
| Gout | 1 | 2020 | 13 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2020 | 26 | 0.190 |
Why?
|
| Uric Acid | 1 | 2020 | 26 | 0.180 |
Why?
|
| Pleural Neoplasms | 2 | 2015 | 51 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 182 | 0.180 |
Why?
|
| Metabolome | 1 | 2019 | 47 | 0.180 |
Why?
|
| Commerce | 1 | 2020 | 81 | 0.170 |
Why?
|
| Adenoviridae | 2 | 2011 | 59 | 0.170 |
Why?
|
| Receptors, Virus | 2 | 2011 | 20 | 0.170 |
Why?
|
| Carcinoma | 2 | 2013 | 94 | 0.170 |
Why?
|
| Amino Acids | 1 | 2019 | 139 | 0.170 |
Why?
|
| Lyases | 1 | 2019 | 51 | 0.170 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2018 | 22 | 0.170 |
Why?
|
| Genomic Imprinting | 1 | 2018 | 35 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 195 | 0.170 |
Why?
|
| Mesothelioma | 2 | 2015 | 135 | 0.170 |
Why?
|
| Glucuronides | 1 | 2018 | 10 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 184 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 1426 | 0.160 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 203 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2018 | 25 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2018 | 56 | 0.160 |
Why?
|
| Acetylcysteine | 2 | 2017 | 58 | 0.160 |
Why?
|
| Alleles | 4 | 2020 | 284 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 303 | 0.150 |
Why?
|
| Phenotype | 4 | 2023 | 650 | 0.150 |
Why?
|
| Hawaii | 4 | 2020 | 1878 | 0.150 |
Why?
|
| Drug Resistance | 3 | 1993 | 93 | 0.150 |
Why?
|
| Longevity | 1 | 2018 | 143 | 0.150 |
Why?
|
| Hepatitis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Carcinogens | 1 | 2017 | 117 | 0.140 |
Why?
|
| Antigens | 2 | 1995 | 56 | 0.140 |
Why?
|
| Cell Membrane Permeability | 2 | 1995 | 49 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 968 | 0.140 |
Why?
|
| Immunophenotyping | 1 | 1995 | 53 | 0.140 |
Why?
|
| Solutions | 1 | 1995 | 60 | 0.130 |
Why?
|
| Nicotine | 3 | 2018 | 238 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 104 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 371 | 0.130 |
Why?
|
| Genome, Human | 5 | 2016 | 112 | 0.130 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 19 | 0.130 |
Why?
|
| DNA | 2 | 2014 | 549 | 0.130 |
Why?
|
| Erythrocytes | 1 | 1995 | 107 | 0.130 |
Why?
|
| Chorion | 1 | 2014 | 8 | 0.130 |
Why?
|
| Amnion | 1 | 2014 | 17 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2015 | 48 | 0.130 |
Why?
|
| Carrier Proteins | 2 | 1994 | 287 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2021 | 1422 | 0.120 |
Why?
|
| Asbestos, Serpentine | 1 | 2013 | 2 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 37 | 0.120 |
Why?
|
| Isoenzymes | 1 | 1994 | 149 | 0.120 |
Why?
|
| Adult | 10 | 2020 | 11034 | 0.120 |
Why?
|
| Body Mass Index | 4 | 2023 | 775 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 57 | 0.120 |
Why?
|
| Epithelium | 1 | 2013 | 74 | 0.120 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2013 | 7 | 0.120 |
Why?
|
| Chromosomal Instability | 1 | 2013 | 21 | 0.120 |
Why?
|
| HMGB1 Protein | 1 | 2013 | 29 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2012 | 1349 | 0.120 |
Why?
|
| Relaxin | 1 | 2013 | 10 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 27 | 0.110 |
Why?
|
| Macrophages | 1 | 2016 | 431 | 0.110 |
Why?
|
| Gene Deletion | 4 | 2017 | 156 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2021 | 18 | 0.110 |
Why?
|
| Mutation | 2 | 2015 | 1023 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2019 | 1802 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 166 | 0.110 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 25 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1152 | 0.110 |
Why?
|
| Premature Birth | 1 | 2013 | 71 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 424 | 0.110 |
Why?
|
| Electrophoresis, Microchip | 1 | 2012 | 21 | 0.110 |
Why?
|
| Taxoids | 1 | 2012 | 36 | 0.110 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 68 | 0.100 |
Why?
|
| Adenoma | 1 | 2013 | 89 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 325 | 0.100 |
Why?
|
| Gene Dosage | 3 | 2017 | 74 | 0.100 |
Why?
|
| Colon | 1 | 2012 | 98 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2016 | 298 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 128 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 528 | 0.090 |
Why?
|
| Risk Factors | 6 | 2017 | 3414 | 0.090 |
Why?
|
| Vitamin B Complex | 1 | 2009 | 5 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 592 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 628 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 2128 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2009 | 18 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 322 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 468 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2001 | 37 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2007 | 6 | 0.080 |
Why?
|
| Pyridines | 1 | 2008 | 113 | 0.080 |
Why?
|
| Receptors, Nicotinic | 1 | 2008 | 91 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 165 | 0.080 |
Why?
|
| beta Catenin | 2 | 2021 | 46 | 0.080 |
Why?
|
| Vegetables | 1 | 2009 | 135 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 859 | 0.080 |
Why?
|
| Risk | 3 | 2014 | 256 | 0.070 |
Why?
|
| Mice | 5 | 2019 | 5668 | 0.070 |
Why?
|
| Pregnancy | 3 | 2020 | 1503 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2011 | 653 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 338 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 24 | 0.070 |
Why?
|
| Cell Movement | 2 | 2021 | 545 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2003 | 67 | 0.070 |
Why?
|
| Base Sequence | 2 | 2021 | 932 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 180 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2016 | 70 | 0.060 |
Why?
|
| Antigens, CD | 2 | 1995 | 116 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 183 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 550 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 455 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2014 | 420 | 0.060 |
Why?
|
| Acute Disease | 2 | 1994 | 141 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 1991 | 756 | 0.060 |
Why?
|
| Computational Biology | 2 | 2016 | 275 | 0.060 |
Why?
|
| Gene Expression | 2 | 2019 | 639 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1149 | 0.060 |
Why?
|
| Microsatellite Repeats | 3 | 2013 | 51 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 114 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 4012 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 480 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2002 | 143 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2021 | 10 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2021 | 5 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2001 | 33 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 21 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 15 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 11 | 0.050 |
Why?
|
| Animals | 5 | 2019 | 14307 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 1993 | 282 | 0.050 |
Why?
|
| Bone Marrow | 3 | 1998 | 34 | 0.050 |
Why?
|
| Microsatellite Instability | 2 | 2013 | 43 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 964 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2020 | 66 | 0.050 |
Why?
|
| United States | 2 | 2021 | 3894 | 0.050 |
Why?
|
| Hyperuricemia | 1 | 2020 | 10 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 247 | 0.050 |
Why?
|
| Metabolomics | 1 | 2019 | 76 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2019 | 58 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 90 | 0.040 |
Why?
|
| Disease Progression | 1 | 2001 | 580 | 0.040 |
Why?
|
| Sirtuins | 1 | 2018 | 12 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 19 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 58 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2018 | 155 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 133 | 0.040 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 8 | 0.040 |
Why?
|
| Haplotypes | 1 | 2018 | 152 | 0.040 |
Why?
|
| Postmenopause | 1 | 2018 | 125 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 1998 | 23 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 423 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 26 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 642 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2018 | 121 | 0.040 |
Why?
|
| Selenium | 1 | 2019 | 144 | 0.040 |
Why?
|
| Logistic Models | 2 | 2011 | 894 | 0.040 |
Why?
|
| Tibia | 1 | 2016 | 18 | 0.040 |
Why?
|
| Femur | 1 | 2016 | 35 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 897 | 0.040 |
Why?
|
| Glutathione | 1 | 2017 | 160 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2016 | 123 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 447 | 0.030 |
Why?
|
| Intracellular Fluid | 1 | 1995 | 26 | 0.030 |
Why?
|
| Vimentin | 1 | 1995 | 32 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 51 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1425 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 50 | 0.030 |
Why?
|
| New York | 1 | 2015 | 69 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 140 | 0.030 |
Why?
|
| Adolescent | 3 | 2020 | 5035 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 605 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 151 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 255 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 1994 | 18 | 0.030 |
Why?
|
| Cytosol | 1 | 1994 | 85 | 0.030 |
Why?
|
| Asbestos, Crocidolite | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Shape | 1 | 2013 | 35 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1994 | 116 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 328 | 0.030 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1993 | 5 | 0.030 |
Why?
|
| Cadherins | 1 | 2013 | 82 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2013 | 2 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1993 | 14 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 52 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 60 | 0.030 |
Why?
|
| Cell Death | 1 | 2013 | 260 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 1992 | 75 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 14 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1992 | 135 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 882 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 211 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1530 | 0.030 |
Why?
|
| Potassium Channels | 1 | 2012 | 73 | 0.030 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 4 | 0.030 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2011 | 24 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2011 | 84 | 0.030 |
Why?
|
| Sex Factors | 1 | 2014 | 859 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2011 | 154 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 1353 | 0.020 |
Why?
|
| Age Factors | 1 | 1993 | 1007 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 1289 | 0.020 |
Why?
|
| Vitamin B 6 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 901 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 13 | 0.020 |
Why?
|
| Proteins | 1 | 2012 | 352 | 0.020 |
Why?
|
| Folic Acid | 1 | 2009 | 46 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 101 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 147 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 1961 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1490 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2007 | 30 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 98 | 0.020 |
Why?
|
| Infant | 2 | 2001 | 1014 | 0.020 |
Why?
|
| Mesoderm | 1 | 2006 | 70 | 0.020 |
Why?
|
| Registries | 1 | 2007 | 330 | 0.020 |
Why?
|
| Cricetinae | 1 | 2006 | 217 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 287 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2006 | 70 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2001 | 1318 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 490 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 522 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 151 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 18 | 0.010 |
Why?
|
| Sulfites | 1 | 2002 | 5 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 159 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2002 | 15 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2006 | 366 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 139 | 0.010 |
Why?
|
| Child | 2 | 2001 | 2875 | 0.010 |
Why?
|
| Karyotyping | 1 | 2001 | 46 | 0.010 |
Why?
|
| Blast Crisis | 1 | 1998 | 2 | 0.010 |
Why?
|
| Finland | 1 | 1998 | 10 | 0.010 |
Why?
|
| Asparaginase | 1 | 1998 | 4 | 0.010 |
Why?
|
| Vincristine | 1 | 1998 | 13 | 0.010 |
Why?
|
| Remission Induction | 1 | 1998 | 18 | 0.010 |
Why?
|
| Prednisone | 1 | 1998 | 26 | 0.010 |
Why?
|
| Cytarabine | 1 | 1998 | 8 | 0.010 |
Why?
|
| Methotrexate | 1 | 1998 | 20 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 52 | 0.010 |
Why?
|
| Recurrence | 1 | 1998 | 125 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 80 | 0.010 |
Why?
|